News

The extended collaboration comes as the Japanese company intends to take a lead candidate into preclinical development, within the area of inflammation. The lead candidate was discovered using

The new patent, number 7,851,506, is also listed in the US Food and Drug Administration’s Approved Drug Products List (the Orange Book). In addition to the newly issued

Takeda filed the lawsuits to enforce several patents that expire in 2016 relating to ACTOS, ACTOplus met, and duetact. Agreements have been reached with: Mylan, Alphapharm, Watson Pharmaceuticals,

The agreement, in the areas of high-technology and knowledge sharing, will entail licensing of manufacturing know-how of products by Dr Reddy’s, local manufacturing of products in Russia, co-development

Tanaproget is a tissue-selective, non-steroidal contraceptive progesterone receptor agonist that has the potential for an improved side effect profile over current steroid-containing contraceptives. The tie up allows the

Morganroth is currently working as ERT’s chairman and chief scientific officer and has served as the chairman of ERT’s board of directors since 1999 and as chief scientific

The application relates to the use of Ergothioneine compositions containing one or more additional nutraceutical compounds to improve a variety of health related factors, including, but not limited

Janssen-Cilag International has also filed a marketing authorisation application (MAA) with the European Medicines Agency for abiraterone acetate. Abiraterone acetate was developed by Ortho Biotech Oncology Research &

The study results revealed that INC424 provided a statistically significant reduction in spleen size in patients with primary MF, post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF).